Navigation Links
Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
Date:5/24/2010

RICHMOND, Calif., May 24 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that data from research and preclinical programs focused on the development of zinc finger DNA-binding protein (ZFP) Therapeutics™ were described in fifteen presentations given by Sangamo scientists and collaborators at the 13th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT).  The meeting was held in Washington, DC from May 17-22, 2010.

"Sangamo's ZFP technology provides an exciting new approach for the development of novel human therapeutics," said Luigi Naldini, M.D., Ph.D., Director of the San Raffaele Telethon Institute for Gene Therapy, Milan, and the principal investigator on several papers presented at the meeting. "ZFP nucleases (ZFNs) enable us to edit the human genome with unprecedented specificity and efficiency. This opens the way to correction of inherited mutations, a potentially revolutionary approach as it can restore a gene's function while preserving its natural regulation, likely overcoming the risks associated with random gene addition approaches. We are using this technology to investigate novel therapies for monogenic diseases and cancer."

The presentations made at the ASGCT meeting covered research and preclinical data from Sangamo's programs and collaborations in human therapeutics and technology development in primary human cells and stem cells.  Therapeutic areas included ZFN-based approaches to infectious diseases such as HIV/AIDS and cytomegalovirus (CMV), monogenic diseases such as sickle cell anemia and epidermolysis bullosa, and oncology.   Positive preclinical data were also presented from experiments using Sangamo's gene regulation technology to up-regulate the vascular endothelial growth factor-A (VEGF-A) gene in an animal model of traumatic brain injury. Philip Gregory, D. Phil., Sangamo's vice president of research and chief scientific officer, made a presentation entitled "Stem Cell Modification with Zinc Finger Nucleases," and chaired a session devoted to stem cell modification. All abstracts for the meeting are available online at http://www.asgct.org/am10/

"Sangamo's technology has the potential to revolutionize the field of cell and gene therapy," stated Barrie Carter, Ph.D., a member of Sangamo's scientific advisory board and the current President of ASGCT. "ZFN technology enables an efficient and precise process for making changes to the DNA sequence of a cell, which is necessary for therapeutic applications of gene-editing.  ZFN-based therapeutics are already being evaluated by Sangamo in human clinical trials in HIV/AIDS and brain cancer. As this technology functions at the DNA level, it can be applied to address numerous diseases for which target genes have been identified."

"The data presented at this meeting highlight the breadth of potential applications for ZFP Therapeutics," said Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer.  "Our ZFP Therapeutic platform is maturing. We have completed four Phase 2 clinical trials, have an ongoing Phase 2b trial of our ZFP activator of VEGF-A, SB-509, in diabetic neuropathy and have three ongoing trials of our ZFN-based technology.  At the same time, with our collaborators, we continue to define and develop new therapeutic opportunities."

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic™ development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFN) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at http://www.sangamo.com/.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics and therapeutic applications of Sangamo's ZFP technology platform to specific human diseases. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to whether clinical trials will validate and support tolerability and efficacy of ZFP Therapeutic approaches, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See Sangamo's SEC filings, and in particular, the risk factors described in the Company's Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
2. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
3. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
4. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
5. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
6. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
7. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
8. Sangamo Announces Pricing of Public Offering of Common Stock
9. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
10. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
11. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
Breaking Biology Technology:
(Date:6/9/2016)... TURKU, Finland , June 9, 2016 ... French National Police deploy Teleste,s video security solution to ensure ... France during the major tournament ... and data communications systems and services, announced today that its ... Police Prefecture to back up public safety across ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):